Target |
Mechanism GP IIb/IIIa antagonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism Sodium-hydrogen exchangers inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism Sodium-hydrogen exchangers inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date11 Jun 2024 |
Sponsor / Collaborator |
Start Date01 Oct 2021 |
Sponsor / Collaborator |
Start Date30 Jun 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
MS-180(Mitsui Chemicals, Inc.) ( GP IIb/IIIa ) | Thromboembolism More | Discontinued |
MS-31050 ( Sodium-hydrogen exchangers ) | Myocardial Ischemia More | Pending |
MS-31038 ( Sodium-hydrogen exchangers ) | Myocardial Ischemia More | Pending |
IMGM ( Sodium-hydrogen exchangers ) | Myocardial Ischemia More | Pending |